Answers are grounded in this paper and cite their sources.
Case report reports the development of type 1 diabetes mellitus after cord blood transplantation in an acute myeloid leukemia patient, highlighting the role of donor-transmitted genetic risk.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative treatment for hematopoietic neoplasms, often causes various autoimmune disease-like conditions. In contrast, allo-HSCT-related type 1 diabetes mellitus is extremely rare. Herein, we report a case of allo-HSCT-related type 1 diabetes mellitus in a patient who had undergone cord blood transplantation (CBT) as a treatment for acute myeloid leukemia. The patient's human leukocyte antigen was replaced with the donor type after transplantation. The donor had a disease-sensitive haplotype. To the best of our knowledge, this is the first reported case of type 1 diabetes mellitus following CBT.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: